Brightsurf Science News & Current Events

August 29, 2004
Global study shows nine factors identify majority of heart attack risk
A major Canadian-led global study has found that the vast majority of heart attacks may be predicted by nine easily measurable factors and that these factors are the same in virtually every region and ethnic group worldwide.

ESC Congress 2004: Atrial fibrillation patients often receive needless treatment
Results of the Euro Heart Survey on atrial fibrillation (AF), presented today, demonstrate that many AF patients receive clot-preventing drugs while not at risk for stroke.

ESC Congress 2004: New study confirms benefits of rimonabant
First year results of the two year trial RIO-Europe, a Phase III clinical study comparing placebo to rimonabant, the first agent in a new therapeutic class known as selective cannabinoid type 1 (CB1) blockers, showed that overweight or obese people taking rimonabant 20mg once daily benefited from a significant reduction in their body weight, waist circumference ┬ĘC a marker of the dangerous abdominal obesity - and improvements in their lipid and glycemic profiles.

Enzyme reins in runaway inflammation; may prove potent drug target
An enzyme found in nearly all animal and human cells acts as a natural brake to prevent potentially deadly runaway inflammation, UCSF scientists have discovered.

ESC Congress 2004: Efficacy and safety of ximelagatran confirmed
Results presented today from the final pooled analysis of SPORTIF III and V1,2 confirm that ximelagatran - the first oral direct thrombin inhibitor (oral DTI) - is as effective as well-controlled warfarin, the current standard anticoagulant treatment for the prevention of stroke in patients with atrial fibrillation (AF), but without the need for coagulation monitoring or individual dose titration.

ESC Congress 2004: Benefits of dronedarone in management of cardiac arrhythmia
Results of the EURIDIS trial (EURopean trial In atrial fibrillation or flutter patients receiving Dronedarone for the maIntenance of Sinus rhythm), announced today at the European Society of Cardiology (ESC 2004) annual meeting, showed that the new antiarrhythmic agent, dronedarone, is highly effective in the prevention of both symptomatic and asymptomatic recurrences of atrial fibrillation (AF)/atrial flutter (AFL), and has a safety profile that is comparable to that observed with placebo in this patient population.

ESC Congress 2004: New insights from the ACTION study
The ACTION (A Coronary Disease Trial Investigating Outcome with NIFEDIPINE GITS) study has now been completed by SOCAR Research in collaboration with an international group of robustly independent experts chaired by Professor Philip A.

ESC Congress 2004: DronedarONe is effective and well-tolerated in prevention of AF recurrence
The findings of the

ESC Congress 2004: Worldwide survey on catheter ablation for human atrial fibrillation
The purpose of this study was to conduct a worldwide survey investigating the methods, efficacy and safety of catheter ablation (CA) of atrial fibrillation (AF).

Advances in tumor angiogenesis - Dendritic cells co-opted to the dark side
Researchers at the University of Pennsylvania School of Medicine discovered that in ovarian cancer immune cells can change into blood-vessel cells, and eventually promote the life-sustaining vasculature of the tumor.

ESC Congress 2004: ICTUS study shows no benefit from early PCI/CABG in high risk unstable angina
Dutch clinical investigators will present data during the Hotline II session on Sunday afternoon, August 29th, ESC Congress 2004, Munich, Germany, showing that modern medical treatment, and angiography followed by PCI or CABG in selected patients (selective invasive strategy), may be equally effective. is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to